Modulation of oral bioavailability of anticancer drugs: From mouse to man

European Journal of Pharmaceutical Sciences

Volumn 12, Issue 2, 2000, Pages 103-110

  Schellens, Jan H M ^a,c   Malingré, Mirte M ^a,b   Kruijtzer, C Marielle F ^a   Bardelmeijer, H A ^a,b   Van Tellingen, Olaf ^b   Schinkel, Alfred H ^a   Beijnen, Jos H ^a,b,c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bioavailability; Cytochrome P450; Docetaxel; Oral administration; P Glycoprotein; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYTOCHROME P450; DOCETAXEL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL;

ANIMAL EXPERIMENT; DRUG BIOAVAILABILITY; DRUG TRANSFORMATION; DRUG TRANSPORT; HUMAN; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033708071     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00153-6     Document Type: Article

References (77)

1. Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression
2. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
3. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
4. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats
5. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
6. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
7. The three mouse multidrug resistance (mdr) genes are expressed in a tissue specific manner in normal mouse tissues
8. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
9. Oral chemotherapy: rationale and future directions
10. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities
11. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
12. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development
13. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan
14. Biochemistry of multidrug resistance mediated by the multidrug transporter
15. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins
16. In vitro techniques for studying drug metabolism
17. Bioavailability of low-dose oral etoposide
18. ABC transporters: from microorganisms to man
19. Differential overexpression of three mdr family members in multidrug-resistant J774.2 mouse cells
20. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinumpretreated ovarian cancer patients
21. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and sequencing study in patients with non-small cell lung cancer
22. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
23. A novel form of mouse cytochrome P450 3A (Cyp3a-16). Its cDNA cloning and expression in fetal liver
24. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
25. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome
26. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
27. Fetus-specific expression of a form of cytochrome P-450 in human livers
28. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice
29. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics
30. Inhibition and induction of cytochrome P450 and the clinical implications
31. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test
32. Grapefruit juice increases felodipine oral bioavailability in humans by decreasing intestinal CYP3A protein expression
33. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
34. Oral paclitaxel in a twice daily dose regimen (abstract)
35. Clinical pharmacology of oral paclitaxel in a dose escalating study
36. Clinical pharmacology of oral paclitaxel in a dose-escalating study (abstract)
37. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein
38. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration
39. Co-administration of cyclosporin enables oral therapy with paclitaxel
40. Mass balance of paclitaxel (Paxene (®)) in humans after both intravenous and oral administration
41. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature
42. Congenital jaundice in rats with a mutation in a multidrug resistance-associated gene
43. Cyclosporin a strongly enhances the oral bioavailability of docetaxel in cancer patients
44. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor
45. Cyclosporin A (CsA) strongly enhances oral bioavailability of paclitaxel (pac) in cancer patients (abstract)
46. The physiological function of drug-transporting P-glycoproteins
47. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
48. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
49. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
50. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
51. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted
52. Genetic polymorphisms in xenobiotic metabolism
53. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
54. Preclinical pharmacokinetics of paclitaxel and docetaxel
55. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16
56. Cellular localization of the multidrug resistance gene product in normal human tissues
57. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
58. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice
59. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
60. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
61. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy
62. Active secretion and enterocytic drug metabolism barriers to drug absorption
63. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
64. Drug metabolism by cytochromes P450 in the liver and small bowel
65. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man
66. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein
67. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918
68. Mouse liver cytochrome P-450 (P-450IIIAm1): its cDNA cloning and inducibility by dexamethasone
69. 1)
70. 1